granulomatosis with polyangiitis (Wegener’s granulomatosis) Ameen Rageh
This document discusses Wegener's granulomatosis (now called granulomatosis with polyangiitis or GPA), a rare multisystem autoimmune disease characterized by necrotizing vasculitis and granulomatous inflammation that commonly involves the respiratory tract and kidneys. Key points include:
- GPA is associated with circulating ANCA antibodies and causes necrotizing inflammation of small to medium vessels.
- Common clinical manifestations involve the upper respiratory tract, lungs, and kidneys. Chest imaging often shows nodules/masses, cavities, ground glass opacities and consolidations.
- Diagnosis is based on clinical features, labs including positive ANCA, and biopsy
The document summarizes various pulmonary manifestations that can occur in patients with systemic lupus erythematosus (SLE). The most common manifestations are pleuritis and pleural effusions, as well as upper respiratory tract infections. Other potential manifestations include acute lupus pneumonitis, interstitial lung disease, pulmonary hypertension, shrinking lung syndrome, pulmonary hemorrhage, and cryptogenic organizing pneumonia. Diagnosis involves imaging tests, pulmonary function tests, biopsy, and ruling out other causes. Treatment depends on the specific manifestation but often involves corticosteroids, immunosuppressants, and other medications.
This document provides an overview of scleroderma and its pulmonary complications from the perspective of an expert in the field. It summarizes that interstitial lung disease is a common complication of scleroderma and may present in various ways. It also reviews treatment approaches for scleroderma-associated interstitial lung disease that have been supported by clinical trials, including cyclophosphamide, mycophenolate, and rituximab.
Pulmonary manifestations of systemic lupus erythematosisdattasrisaila
Acute lupus pneumonitis, pulmonary hemorrhage, bronchiolitis obliterans organizing pneumonia, constrictive bronchiolitis, chronic interstitial pneumonitis and fibrosis, and pulmonary vascular disease are the main pulmonary manifestations of systemic lupus erythematosus. Imaging findings vary depending on the specific manifestation but may include ground glass opacities, consolidation, nodules, septal thickening, and signs of pulmonary hypertension. Pulmonary infections, especially tuberculosis, are also important indirect pulmonary complications of SLE due to immunosuppression from the disease or its treatments.
This document provides an overview of sarcoidosis, including:
- It is a multisystem granulomatous disorder of unknown cause that commonly affects the lungs, skin and eyes.
- Risk factors include genetics and environmental exposures, and it has the highest rates in the United States and Sweden.
- Clinical presentation varies from asymptomatic to involvement of multiple organ systems. Lung involvement is most common and is staged based on chest x-ray findings.
- Diagnosis involves ruling out other causes and may include biopsy showing non-caseating granulomas. Treatment involves corticosteroids and prognosis is generally good with many experiencing remission.
This document summarizes pulmonary hypertension and its management. It discusses the pulmonary circulation and pressures, types and classification of pulmonary hypertension, pathogenesis involving various molecular pathways, clinical diagnosis using echocardiography, right heart catheterization, and treatment goals and strategies. The main treatment approaches discussed are calcium channel blockers, prostanoids, endothelin receptor antagonists, phosphodiesterase inhibitors, and soluble guanylate cyclase stimulators. The goals of treatment are to palliate symptoms, improve exercise tolerance and right ventricular function, and strive to improve survival rates.
The document discusses the diagnostic approach and treatment of interstitial lung disease (ILD). ILD refers to over 100 lung disorders that share clinical features and affect the lung interstitium. The evaluation of ILD involves obtaining a thorough medical history focusing on exposures, symptoms, and underlying conditions. Physical exams may reveal crackles or clubbing. Tests include pulmonary function tests, imaging, and tissue sampling. Treatment depends on the underlying cause but may include immunosuppressants, antifibrotic drugs, oxygen therapy, and lung transplantation. A multidisciplinary team is needed for accurate diagnosis and management of ILD.
This document summarizes various connective tissue disease-associated interstitial lung diseases. It describes common intrathoracic manifestations and imaging findings for conditions like rheumatoid arthritis, progressive systemic sclerosis, systemic lupus erythematosus, and polymyositis/dermatomyositis. For each condition, it lists typical radiological patterns seen on CT such as ground glass opacities, reticulation, consolidation, and honeycombing. Photomicrographs are also included to illustrate histopathological findings for some of the interstitial lung diseases.
granulomatosis with polyangiitis (Wegener’s granulomatosis) Ameen Rageh
This document discusses Wegener's granulomatosis (now called granulomatosis with polyangiitis or GPA), a rare multisystem autoimmune disease characterized by necrotizing vasculitis and granulomatous inflammation that commonly involves the respiratory tract and kidneys. Key points include:
- GPA is associated with circulating ANCA antibodies and causes necrotizing inflammation of small to medium vessels.
- Common clinical manifestations involve the upper respiratory tract, lungs, and kidneys. Chest imaging often shows nodules/masses, cavities, ground glass opacities and consolidations.
- Diagnosis is based on clinical features, labs including positive ANCA, and biopsy
The document summarizes various pulmonary manifestations that can occur in patients with systemic lupus erythematosus (SLE). The most common manifestations are pleuritis and pleural effusions, as well as upper respiratory tract infections. Other potential manifestations include acute lupus pneumonitis, interstitial lung disease, pulmonary hypertension, shrinking lung syndrome, pulmonary hemorrhage, and cryptogenic organizing pneumonia. Diagnosis involves imaging tests, pulmonary function tests, biopsy, and ruling out other causes. Treatment depends on the specific manifestation but often involves corticosteroids, immunosuppressants, and other medications.
This document provides an overview of scleroderma and its pulmonary complications from the perspective of an expert in the field. It summarizes that interstitial lung disease is a common complication of scleroderma and may present in various ways. It also reviews treatment approaches for scleroderma-associated interstitial lung disease that have been supported by clinical trials, including cyclophosphamide, mycophenolate, and rituximab.
Pulmonary manifestations of systemic lupus erythematosisdattasrisaila
Acute lupus pneumonitis, pulmonary hemorrhage, bronchiolitis obliterans organizing pneumonia, constrictive bronchiolitis, chronic interstitial pneumonitis and fibrosis, and pulmonary vascular disease are the main pulmonary manifestations of systemic lupus erythematosus. Imaging findings vary depending on the specific manifestation but may include ground glass opacities, consolidation, nodules, septal thickening, and signs of pulmonary hypertension. Pulmonary infections, especially tuberculosis, are also important indirect pulmonary complications of SLE due to immunosuppression from the disease or its treatments.
This document provides an overview of sarcoidosis, including:
- It is a multisystem granulomatous disorder of unknown cause that commonly affects the lungs, skin and eyes.
- Risk factors include genetics and environmental exposures, and it has the highest rates in the United States and Sweden.
- Clinical presentation varies from asymptomatic to involvement of multiple organ systems. Lung involvement is most common and is staged based on chest x-ray findings.
- Diagnosis involves ruling out other causes and may include biopsy showing non-caseating granulomas. Treatment involves corticosteroids and prognosis is generally good with many experiencing remission.
This document summarizes pulmonary hypertension and its management. It discusses the pulmonary circulation and pressures, types and classification of pulmonary hypertension, pathogenesis involving various molecular pathways, clinical diagnosis using echocardiography, right heart catheterization, and treatment goals and strategies. The main treatment approaches discussed are calcium channel blockers, prostanoids, endothelin receptor antagonists, phosphodiesterase inhibitors, and soluble guanylate cyclase stimulators. The goals of treatment are to palliate symptoms, improve exercise tolerance and right ventricular function, and strive to improve survival rates.
The document discusses the diagnostic approach and treatment of interstitial lung disease (ILD). ILD refers to over 100 lung disorders that share clinical features and affect the lung interstitium. The evaluation of ILD involves obtaining a thorough medical history focusing on exposures, symptoms, and underlying conditions. Physical exams may reveal crackles or clubbing. Tests include pulmonary function tests, imaging, and tissue sampling. Treatment depends on the underlying cause but may include immunosuppressants, antifibrotic drugs, oxygen therapy, and lung transplantation. A multidisciplinary team is needed for accurate diagnosis and management of ILD.
This document summarizes various connective tissue disease-associated interstitial lung diseases. It describes common intrathoracic manifestations and imaging findings for conditions like rheumatoid arthritis, progressive systemic sclerosis, systemic lupus erythematosus, and polymyositis/dermatomyositis. For each condition, it lists typical radiological patterns seen on CT such as ground glass opacities, reticulation, consolidation, and honeycombing. Photomicrographs are also included to illustrate histopathological findings for some of the interstitial lung diseases.
DIAGNOSIS & MANAGEMENT OF PULMONARY HYPERTENSIONKamal Bharathi
Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure ≥25 mm Hg at rest, measured during right heart catheterization. There is still insufficient evidence to add an exercise criterion to this definition. The term pulmonary arterial hypertension (PAH) describes a subpopulation of patients with PH characterized hemodynamically by the presence of pre-capillary PH including an end-expiratory pulmonary artery wedge pressure (PAWP) ≤15 mm Hg and a pulmonary vascular resistance >3 Wood units. Right heart catheterization remains essential for a diagnosis of PH or PAH. This procedure requires further standardization, including uniformity of the pressure transducer zero level at the midthoracic line, which is at the level of the left atrium. One of the most common problems in the diagnostic workup of patients with PH is the distinction between PAH and PH due to left heart failure with preserved ejection fraction (HFpEF). A normal PAWP does not rule out the presence of HFpEF. Volume or exercise challenge during right heart catheterization may be useful to unmask the presence of left heart disease, but both tools require further evaluation before their use in general practice can be recommended. Early diagnosis of PAH remains difficult, and screening programs in asymptomatic patients are feasible only in high-risk populations, particularly in patients with systemic sclerosis, for whom recent data suggest that a combination of clinical assessment and pulmonary function testing including diffusion capacity for carbon monoxide, biomarkers, and echocardiography has a higher predictive value than echocardiography alone.
This document discusses interstitial lung disease (ILD) associated with connective tissue diseases (CTDs). It begins by providing background on ILD and defining common presentations. It then discusses the classification of ILD and patterns associated with different CTDs. Common CTDs that can cause ILD are described such as systemic sclerosis, rheumatoid arthritis, and polymyositis/dermatomyositis. Risk factors, pathophysiology, epidemiology, clinical presentation, investigations including radiography and antibodies, and biomarkers for ILD associated with CTDs are summarized. Specific CT features that can help differentiate CTD-ILD from idiopathic pulmonary fibrosis are also outlined.
Acute Respiratory Distress Syndrome (ARDS) is a sudden, progressive form of respiratory failure characterized by severe dyspnea, hypoxemia, and decreased lung compliance. It develops from direct or indirect lung injuries and is thought to be caused by stimulation of the inflammatory and immune systems, resulting in leakage of fluid into the lungs. The clinical progression of ARDS involves exudative, proliferative, and fibrotic phases that can lead to respiratory failure if not promptly treated with oxygen supplementation, mechanical ventilation, and other supportive therapies.
Sarcoidosis is a multisystem disorder characterized by the formation of noncaseating granulomas in multiple organs. It most commonly involves the lungs, lymph nodes, skin, and eyes. The cause is unknown but believed to be due to an abnormal immune response to unknown antigens in genetically predisposed individuals. Diagnosis is based on clinical features and identification of granulomas on biopsy, and exclusion of other conditions. While often asymptomatic, it can cause respiratory symptoms as well as involvement of other organs. Treatment involves corticosteroids, with hydroxychloroquine or methotrexate as steroid-sparing options. Prognosis is generally good, though some degree of permanent organ dysfunction occurs in about half of
This document discusses asthma-COPD overlap syndrome (ACOS). It defines asthma and COPD, noting their differences and similarities. Both are chronic inflammatory airway diseases but COPD is characterized by persistent airflow limitation and progressive lung function decline while asthma is often reversible. The document then discusses clinical features that can help distinguish asthma from COPD. It notes that some patients have features of both diseases, termed ACOS. Spirometry, biomarkers, imaging and response to treatment are discussed to help identify ACOS. The inflammatory patterns in asthma and COPD are compared, showing that eosinophilic inflammation is more prominent in asthma while neutrophilic inflammation dominates in COPD.
Granulomatosis with polyangiitis (GPA), formerly known as Wegener's granulomatosis, is a rare autoimmune disease characterized by inflammation of blood vessels. It commonly involves the upper and lower respiratory tracts and kidneys. The disease was first described in 1931 and recognized as a distinct clinical entity in 1936. Common symptoms include nasal inflammation, sinusitis, lung nodules, alveolar hemorrhage, and necrotizing glomerulonephritis. Diagnosis involves meeting criteria established by the American College of Rheumatology or the 2012 revised Chapel Hill criteria through clinical evaluation, biopsy, and ANCA testing. Treatment involves immunosuppressive medications.
This document provides information on sarcoidosis, a multisystem chronic inflammatory disease characterized by non-caseating granulomas. It discusses the epidemiology, etiology, clinical presentation, pathology, diagnosis and systems involvement of the disease. Sarcoidosis most commonly affects the lungs and lymph nodes, presenting as bilateral hilar lymphadenopathy. The cause is unknown but believed to involve a disordered immune response in genetically predisposed individuals. Diagnosis is based on clinical features along with identification of non-caseating granulomas in biopsy specimens.
This document discusses respiratory failure, which occurs when the respiratory system fails in gas exchange. It defines two main types - hypoxemic respiratory failure, defined as low blood oxygen, and hypercapnic respiratory failure, defined as high blood carbon dioxide. The document then covers the anatomy and physiology of respiration, diagnostic evaluation of respiratory failure, treatment including mechanical ventilation, and specific causes of respiratory failure like infection, airway obstruction, and cardiac issues.
Scleroderma is an autoimmune connective tissue disease that causes hardening of the skin and internal organs. It is classified into limited and diffuse subtypes based on the extent of skin involvement. Raynaud's phenomenon, skin thickening, and pulmonary and gastrointestinal issues are common clinical manifestations. The underlying pathogenesis involves vascular dysfunction, immune dysregulation, and fibrosis. Management focuses on treating individual organ system complications. Prognosis depends on the specific organ systems affected and can range from relatively mild to severe with significant morbidity and mortality.
Fourth Universal Definition Of Myocardial Infarction (2018)magdy elmasry
The document discusses the definition and diagnosis of heart attacks. It notes that there has been confusion over how to diagnose heart attacks, but that new 2018 guidelines aim to provide clarity. The guidelines define myocardial infarction based on elevated troponin levels, as well as symptoms and other diagnostic criteria. They distinguish between types of heart attacks based on their underlying causes, such as plaque rupture or an imbalance of oxygen supply and demand. The guidelines emphasize integrating clinical findings, electrocardiograms, imaging, and lab results over time to arrive at an accurate diagnosis.
Management of parapneumonic effusion and empyemaDileep Benji
Any pleural effusion associated with bacterial pneumonia,lung abscess or bronchiectasis is defined as parapneumonic effusion.Presence of pus in pleural space is called empyema. Pathogenesis,bacteriology,clinical presentation,diagnosis,management has been described in this powerpoint presentation.
This document provides an overview of the diagnosis and management of Acute Respiratory Distress Syndrome (ARDS). It begins with defining ARDS and discussing the Berlin definition. It then covers risk factors, etiology, clinical course, pathophysiology, differential diagnosis, and management approaches. The management section emphasizes the importance of lung-protective ventilation with low tidal volumes to prevent ventilator-induced lung injury in ARDS patients.
This document discusses the pulmonary manifestations of connective tissue disorders. It covers several conditions including rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis. Key points include that interstitial lung disease is a major complication and cause of death. Specific lung diseases discussed include pulmonary hypertension, diffuse alveolar hemorrhage, lupus pneumonitis, and necrobiotic nodules. Treatment involves immunosuppression with medications like cyclophosphamide and mycophenolate mofetil.
ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) .BY DR.Mohammad Abdeljawad Mohammad Abdeljawad
Acute respiratory distress syndrome (ARDS) is an acute lung injury characterized by increased pulmonary vascular permeability and loss of aerated lung tissue. It can be caused by sepsis, pneumonia, or other clinical insults. The Berlin definition classifies ARDS as mild, moderate, or severe based on hypoxemia levels. A diagnosis of ARDS requires onset within one week of a known clinical insult and bilateral opacities on chest imaging. While invasive tests provide limited utility, bronchoscopy and bronchoalveolar lavage may be used to diagnose atypical cases or rule out other conditions.
This document discusses interstitial lung diseases (ILD), also known as diffuse parenchymal lung diseases (DPLD). It provides the following key points:
1. ILD can be caused by over 200 diseases that result in damage to the lung interstitium. Common causes include occupational exposures, collagen vascular diseases, drugs, infections, and idiopathic interstitial pneumonias.
2. Accurately diagnosing ILD requires a multidisciplinary approach including clinical evaluation, radiology such as high-resolution CT, and pathology including surgical lung biopsy.
3. Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and
This document discusses idiopathic interstitial pneumonias other than idiopathic pulmonary fibrosis. It provides the revised ATS/ERS classification of idiopathic interstitial pneumonias and describes non-specific interstitial pneumonia (NSIP) and cryptogenic organizing pneumonia (COP) in detail. NSIP is characterized by a uniform pattern of interstitial inflammation and fibrosis. It commonly occurs in connective tissue diseases and has a good prognosis with treatment. COP is defined by organizing pneumonia in the absence of an identifiable cause, and presents with patchy consolidations that are typically peripheral and migratory.
This document provides an overview of chest x-ray (CXR) basics and techniques. It discusses the main types of radiologic imaging used for pulmonary examinations, including plain CXR, CT, ultrasound and others. The bulk of the document focuses on performing and interpreting plain CXRs, outlining the key steps of evaluating technical quality, anatomical structures, and differentiating common radiographic findings such as consolidation, cavitary lesions, and pulmonary nodules. It provides examples of normal and abnormal CXR presentations of various pulmonary diseases.
Pulmonary embolism results from a blood clot blocking the pulmonary arteries, usually from a deep vein thrombosis. Risk factors include immobilization, leg fractures or surgery, hypercoagulable states, proximal DVTs, strokes, and orthopedic surgeries. Symptoms are tachycardia, dyspnea, chest pain, and hypoxia. Tests include ECGs showing abnormalities, chest x-rays sometimes showing infiltrates, blood gas tests showing hypoxemia, and CT or angiogram to detect emboli. Treatment involves anticoagulation with heparin or low molecular weight heparin, thrombolysis for unstable patients, and embolectomy for severe cases.
This document discusses eosinophilic lung diseases and provides information on eosinophils, their functions, and classification of eosinophilic lung diseases. It summarizes several types of eosinophilic pneumonias including:
1. Loeffler's syndrome (simple pulmonary eosinophilia), which is characterized by transient migratory pulmonary infiltrates, eosinophilia, and mild respiratory symptoms that typically resolve within 1-2 weeks.
2. Drug and toxin-induced pulmonary eosinophilic syndromes, which can range from mild Loeffler's-like illness to severe respiratory failure, and typically resolve after eliminating the causative agent.
3. Idiopathic acute e
Dr. Melaku Y. will present on acute respiratory distress syndrome (ARDS) and be moderated by Dr. Endashaw and Dr. Dejene. ARDS is a clinical syndrome characterized by rapid onset of severe breathing difficulties, low oxygen levels, and diffuse lung infiltrates leading to respiratory failure. It has multiple underlying causes and stages of severity. Treatment focuses on managing the underlying condition, limiting lung injury from mechanical ventilation, and maintaining optimal fluid levels.
Scleroderma Associated Lung Disease is presented by
Jane Dematte MD, MBA, Director, ILD program
Division of Pulmonary and Critical Care, Northwestern Feinberg School of Medicine
The Role of Extracorporeal Photopheresis in Scleroderma is presented by
Jaehyuk Choi
Assistant Professor in the Department of Dermatology
Director of the Extracorporeal Photopherisis Unit
DIAGNOSIS & MANAGEMENT OF PULMONARY HYPERTENSIONKamal Bharathi
Pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure ≥25 mm Hg at rest, measured during right heart catheterization. There is still insufficient evidence to add an exercise criterion to this definition. The term pulmonary arterial hypertension (PAH) describes a subpopulation of patients with PH characterized hemodynamically by the presence of pre-capillary PH including an end-expiratory pulmonary artery wedge pressure (PAWP) ≤15 mm Hg and a pulmonary vascular resistance >3 Wood units. Right heart catheterization remains essential for a diagnosis of PH or PAH. This procedure requires further standardization, including uniformity of the pressure transducer zero level at the midthoracic line, which is at the level of the left atrium. One of the most common problems in the diagnostic workup of patients with PH is the distinction between PAH and PH due to left heart failure with preserved ejection fraction (HFpEF). A normal PAWP does not rule out the presence of HFpEF. Volume or exercise challenge during right heart catheterization may be useful to unmask the presence of left heart disease, but both tools require further evaluation before their use in general practice can be recommended. Early diagnosis of PAH remains difficult, and screening programs in asymptomatic patients are feasible only in high-risk populations, particularly in patients with systemic sclerosis, for whom recent data suggest that a combination of clinical assessment and pulmonary function testing including diffusion capacity for carbon monoxide, biomarkers, and echocardiography has a higher predictive value than echocardiography alone.
This document discusses interstitial lung disease (ILD) associated with connective tissue diseases (CTDs). It begins by providing background on ILD and defining common presentations. It then discusses the classification of ILD and patterns associated with different CTDs. Common CTDs that can cause ILD are described such as systemic sclerosis, rheumatoid arthritis, and polymyositis/dermatomyositis. Risk factors, pathophysiology, epidemiology, clinical presentation, investigations including radiography and antibodies, and biomarkers for ILD associated with CTDs are summarized. Specific CT features that can help differentiate CTD-ILD from idiopathic pulmonary fibrosis are also outlined.
Acute Respiratory Distress Syndrome (ARDS) is a sudden, progressive form of respiratory failure characterized by severe dyspnea, hypoxemia, and decreased lung compliance. It develops from direct or indirect lung injuries and is thought to be caused by stimulation of the inflammatory and immune systems, resulting in leakage of fluid into the lungs. The clinical progression of ARDS involves exudative, proliferative, and fibrotic phases that can lead to respiratory failure if not promptly treated with oxygen supplementation, mechanical ventilation, and other supportive therapies.
Sarcoidosis is a multisystem disorder characterized by the formation of noncaseating granulomas in multiple organs. It most commonly involves the lungs, lymph nodes, skin, and eyes. The cause is unknown but believed to be due to an abnormal immune response to unknown antigens in genetically predisposed individuals. Diagnosis is based on clinical features and identification of granulomas on biopsy, and exclusion of other conditions. While often asymptomatic, it can cause respiratory symptoms as well as involvement of other organs. Treatment involves corticosteroids, with hydroxychloroquine or methotrexate as steroid-sparing options. Prognosis is generally good, though some degree of permanent organ dysfunction occurs in about half of
This document discusses asthma-COPD overlap syndrome (ACOS). It defines asthma and COPD, noting their differences and similarities. Both are chronic inflammatory airway diseases but COPD is characterized by persistent airflow limitation and progressive lung function decline while asthma is often reversible. The document then discusses clinical features that can help distinguish asthma from COPD. It notes that some patients have features of both diseases, termed ACOS. Spirometry, biomarkers, imaging and response to treatment are discussed to help identify ACOS. The inflammatory patterns in asthma and COPD are compared, showing that eosinophilic inflammation is more prominent in asthma while neutrophilic inflammation dominates in COPD.
Granulomatosis with polyangiitis (GPA), formerly known as Wegener's granulomatosis, is a rare autoimmune disease characterized by inflammation of blood vessels. It commonly involves the upper and lower respiratory tracts and kidneys. The disease was first described in 1931 and recognized as a distinct clinical entity in 1936. Common symptoms include nasal inflammation, sinusitis, lung nodules, alveolar hemorrhage, and necrotizing glomerulonephritis. Diagnosis involves meeting criteria established by the American College of Rheumatology or the 2012 revised Chapel Hill criteria through clinical evaluation, biopsy, and ANCA testing. Treatment involves immunosuppressive medications.
This document provides information on sarcoidosis, a multisystem chronic inflammatory disease characterized by non-caseating granulomas. It discusses the epidemiology, etiology, clinical presentation, pathology, diagnosis and systems involvement of the disease. Sarcoidosis most commonly affects the lungs and lymph nodes, presenting as bilateral hilar lymphadenopathy. The cause is unknown but believed to involve a disordered immune response in genetically predisposed individuals. Diagnosis is based on clinical features along with identification of non-caseating granulomas in biopsy specimens.
This document discusses respiratory failure, which occurs when the respiratory system fails in gas exchange. It defines two main types - hypoxemic respiratory failure, defined as low blood oxygen, and hypercapnic respiratory failure, defined as high blood carbon dioxide. The document then covers the anatomy and physiology of respiration, diagnostic evaluation of respiratory failure, treatment including mechanical ventilation, and specific causes of respiratory failure like infection, airway obstruction, and cardiac issues.
Scleroderma is an autoimmune connective tissue disease that causes hardening of the skin and internal organs. It is classified into limited and diffuse subtypes based on the extent of skin involvement. Raynaud's phenomenon, skin thickening, and pulmonary and gastrointestinal issues are common clinical manifestations. The underlying pathogenesis involves vascular dysfunction, immune dysregulation, and fibrosis. Management focuses on treating individual organ system complications. Prognosis depends on the specific organ systems affected and can range from relatively mild to severe with significant morbidity and mortality.
Fourth Universal Definition Of Myocardial Infarction (2018)magdy elmasry
The document discusses the definition and diagnosis of heart attacks. It notes that there has been confusion over how to diagnose heart attacks, but that new 2018 guidelines aim to provide clarity. The guidelines define myocardial infarction based on elevated troponin levels, as well as symptoms and other diagnostic criteria. They distinguish between types of heart attacks based on their underlying causes, such as plaque rupture or an imbalance of oxygen supply and demand. The guidelines emphasize integrating clinical findings, electrocardiograms, imaging, and lab results over time to arrive at an accurate diagnosis.
Management of parapneumonic effusion and empyemaDileep Benji
Any pleural effusion associated with bacterial pneumonia,lung abscess or bronchiectasis is defined as parapneumonic effusion.Presence of pus in pleural space is called empyema. Pathogenesis,bacteriology,clinical presentation,diagnosis,management has been described in this powerpoint presentation.
This document provides an overview of the diagnosis and management of Acute Respiratory Distress Syndrome (ARDS). It begins with defining ARDS and discussing the Berlin definition. It then covers risk factors, etiology, clinical course, pathophysiology, differential diagnosis, and management approaches. The management section emphasizes the importance of lung-protective ventilation with low tidal volumes to prevent ventilator-induced lung injury in ARDS patients.
This document discusses the pulmonary manifestations of connective tissue disorders. It covers several conditions including rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis. Key points include that interstitial lung disease is a major complication and cause of death. Specific lung diseases discussed include pulmonary hypertension, diffuse alveolar hemorrhage, lupus pneumonitis, and necrobiotic nodules. Treatment involves immunosuppression with medications like cyclophosphamide and mycophenolate mofetil.
ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) .BY DR.Mohammad Abdeljawad Mohammad Abdeljawad
Acute respiratory distress syndrome (ARDS) is an acute lung injury characterized by increased pulmonary vascular permeability and loss of aerated lung tissue. It can be caused by sepsis, pneumonia, or other clinical insults. The Berlin definition classifies ARDS as mild, moderate, or severe based on hypoxemia levels. A diagnosis of ARDS requires onset within one week of a known clinical insult and bilateral opacities on chest imaging. While invasive tests provide limited utility, bronchoscopy and bronchoalveolar lavage may be used to diagnose atypical cases or rule out other conditions.
This document discusses interstitial lung diseases (ILD), also known as diffuse parenchymal lung diseases (DPLD). It provides the following key points:
1. ILD can be caused by over 200 diseases that result in damage to the lung interstitium. Common causes include occupational exposures, collagen vascular diseases, drugs, infections, and idiopathic interstitial pneumonias.
2. Accurately diagnosing ILD requires a multidisciplinary approach including clinical evaluation, radiology such as high-resolution CT, and pathology including surgical lung biopsy.
3. Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and
This document discusses idiopathic interstitial pneumonias other than idiopathic pulmonary fibrosis. It provides the revised ATS/ERS classification of idiopathic interstitial pneumonias and describes non-specific interstitial pneumonia (NSIP) and cryptogenic organizing pneumonia (COP) in detail. NSIP is characterized by a uniform pattern of interstitial inflammation and fibrosis. It commonly occurs in connective tissue diseases and has a good prognosis with treatment. COP is defined by organizing pneumonia in the absence of an identifiable cause, and presents with patchy consolidations that are typically peripheral and migratory.
This document provides an overview of chest x-ray (CXR) basics and techniques. It discusses the main types of radiologic imaging used for pulmonary examinations, including plain CXR, CT, ultrasound and others. The bulk of the document focuses on performing and interpreting plain CXRs, outlining the key steps of evaluating technical quality, anatomical structures, and differentiating common radiographic findings such as consolidation, cavitary lesions, and pulmonary nodules. It provides examples of normal and abnormal CXR presentations of various pulmonary diseases.
Pulmonary embolism results from a blood clot blocking the pulmonary arteries, usually from a deep vein thrombosis. Risk factors include immobilization, leg fractures or surgery, hypercoagulable states, proximal DVTs, strokes, and orthopedic surgeries. Symptoms are tachycardia, dyspnea, chest pain, and hypoxia. Tests include ECGs showing abnormalities, chest x-rays sometimes showing infiltrates, blood gas tests showing hypoxemia, and CT or angiogram to detect emboli. Treatment involves anticoagulation with heparin or low molecular weight heparin, thrombolysis for unstable patients, and embolectomy for severe cases.
This document discusses eosinophilic lung diseases and provides information on eosinophils, their functions, and classification of eosinophilic lung diseases. It summarizes several types of eosinophilic pneumonias including:
1. Loeffler's syndrome (simple pulmonary eosinophilia), which is characterized by transient migratory pulmonary infiltrates, eosinophilia, and mild respiratory symptoms that typically resolve within 1-2 weeks.
2. Drug and toxin-induced pulmonary eosinophilic syndromes, which can range from mild Loeffler's-like illness to severe respiratory failure, and typically resolve after eliminating the causative agent.
3. Idiopathic acute e
Dr. Melaku Y. will present on acute respiratory distress syndrome (ARDS) and be moderated by Dr. Endashaw and Dr. Dejene. ARDS is a clinical syndrome characterized by rapid onset of severe breathing difficulties, low oxygen levels, and diffuse lung infiltrates leading to respiratory failure. It has multiple underlying causes and stages of severity. Treatment focuses on managing the underlying condition, limiting lung injury from mechanical ventilation, and maintaining optimal fluid levels.
Scleroderma Associated Lung Disease is presented by
Jane Dematte MD, MBA, Director, ILD program
Division of Pulmonary and Critical Care, Northwestern Feinberg School of Medicine
The Role of Extracorporeal Photopheresis in Scleroderma is presented by
Jaehyuk Choi
Assistant Professor in the Department of Dermatology
Director of the Extracorporeal Photopherisis Unit
Respiratory Complication Of Rheumatic Diseasedrmomusa
This document discusses respiratory complications of rheumatic diseases. It covers causes of diffuse parenchymal lung disease including infections, drugs, and connective tissue diseases. Clinical evaluation involves assessing symptoms, signs, imaging like HRCT, lung function tests, and biopsies. Specific lung manifestations are discussed for diseases like rheumatoid arthritis, SLE, and scleroderma. Drugs that can cause interstitial lung disease or other pulmonary complications are also outlined. Future areas of research are mentioned.
This document summarizes the immune mechanisms involved in systemic juvenile idiopathic arthritis (sJIA). It discusses how sJIA is characterized by excessive inflammation driven by cytokines like interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and interleukin-18 (IL-18). These cytokines promote inflammation by recruiting and activating immune cells. While the triggers for overproduction of these cytokines in sJIA are unknown, they lead to systemic symptoms and joint damage. The document also reviews efforts to understand disease heterogeneity and developing anti-inflammatory treatments targeting these cytokines.
Bethany Doerfler MS, RD, LDN discusses top nutrition concerns of scleroderma patients, as well as the results of a recent medical nutrition therapy study. She also discusses strategies for healthy eating, combating GI issues, maintaining muscle, a Mediterranean diet, supplements and more.
This document provides information on erectile dysfunction (ED) in patients with scleroderma. It defines ED and scleroderma, noting that 41.6% of scleroderma patients experience moderate to severe ED. ED in scleroderma is associated with more severe organ involvement. The document reviews the physiology of erections, risk factors for ED, and how scleroderma impacts penile blood vessels and smooth muscle function. It outlines the evaluation of ED, including history, exam, questionnaires, and potential labs/imaging. Finally, the document discusses treatment options for ED, including oral medications, injections, devices, and penile implants.
Dr. Dean Schraufnagel from the University of Illinois at Chicago presented information about ILD at a Scleroderma Patient Education Conference on Saturday, March 15, 2014 which was hosted by the Scleroderma Foundation, Greater Chicago Chapter.
A patient's inspiring journey and practical tips that are applicable to everyone. Learn how to strengthen certain parts of your body as well as modify exercises to maintain physical health while coping with scleroderma.
What Should I Eat includes information and answers to patient questions regarding diet, nutrition and scleroderma. It is presented by Bethany Doerfler, MS, RD, LDN
Sleep is significantly disturbed for various reasons in chronic illnesses. Treating the sleep disturbance concomitantly with the underlying illness may lead to improved quality of life.
Sleep, depression and pain are interdependent symptoms. Hrayr Attarian, MD discusses sleep in chronic illnesses with a focus on scleroderma.
Benjamin Korman, MD discusses the genetics of scleroderma and the genomic era. Genetics and genomics are complicated, and getting more so every day. Every patient is genetically unique, but new technology will make it easier to understand individuals’ genetic susceptibility to disease and response to therapy.
Pulmonary arterial hypertension (PAH) is high blood pressure in the pulmonary arteries of the lungs. It can be caused by various conditions and is diagnosed through tests like echocardiograms, pulmonary function tests, and right heart catheterization. As PAH progresses, the increased pressure in the lungs puts strain on the right side of the heart. Treatment aims to relieve symptoms and slow disease progression through oral medications, inhaled treatments, IV therapies, and possibly lung transplantation in severe cases.
Skin Complications in Scleroderma
Emily L Keimig, MS, MD Clinical Instructor Department of Dermatology
Presented at the Scleroderma Patient Education Conference, Saturday, October 19, 2013 at Northwestern Memorial Hospital.
Hosted by the Scleroderma Foundation, Greater Chicago Chapter and the Northwestern Scleroderma Program.
Pulmonary Arterial Hypertension: The Other High Blood Pressure and its association with scleroderma is presented by
Micheal J. Cuttica MD, MS, Assistant Professor of Medicine, Director; Northwestern Pulmonary Hypertension Program, Northwestern University
This document provides information on systemic sclerosis (SSc), a chronic autoimmune disease characterized by thickening and hardening of the skin, and involvement of internal organs. It can present as either limited or diffuse cutaneous forms. Key clinical features include Raynaud's phenomenon, skin thickening and tightening, digital pitting scars, and internal organ involvement such as interstitial lung disease, gastrointestinal issues, and renal crisis. Diagnosis involves clinical examination and the presence of autoantibodies. Differential diagnoses include other conditions presenting with similar skin or vascular changes. Complications can affect multiple organ systems and are a leading cause of mortality.
Este documento discute os meios de transporte automóvel versus bicicleta. Ele descreve uma pesquisa sobre os hábitos de mobilidade urbana e os motivos pelos quais as pessoas usam excessivamente carros. Também relata os resultados de um inquérito que mostra que as pessoas preferem bicicletas, mas citam falta de segurança e infraestrutura como barreiras para seu uso.
Lawrence S. Zachary, M.D. from the University of Chicago presents on Fat Transfer to the upper and lower extremities in patients with Raynaud's Phenomenon.
Northwestern University Feinberg School of Medicine is studying the effects of a Mediterranean diet on patients with advanced scleroderma as part of the Medical Nutrition Therapy for Patients with Advanced Scleroderma project. A Mediterranean diet focuses on fruits and vegetables, whole grains, healthy fats and lean proteins and is thought to reduce inflammation. The document provides nutrition advice for scleroderma patients, including tips on managing common GI issues, maintaining muscle mass through adequate protein intake, and determining if supplements are needed.
This talk will review the best practices for monitoring for the early detection of interstitial lung disease (ILD) and pulmonary hypertension (PH), the two most common and serious lung diseases that occur in patients with scleroderma. It will also cover the many new medications approved for the treatment of ILD and PH and when these medications are indicated. The goal is for patients with scleroderma to understand the recent advances in the diagnosis and treatment of scleroderma-associated lung diseases that are leading to improved outcomes.
This document provides an overview of a case of a 70-year-old African American female presenting with acute respiratory distress and signs of a non-ST elevated myocardial infarction (NSTEMI). It discusses her medical history of cardiovascular risk factors and presents her vital signs, physical exam findings, laboratory and imaging results supporting the diagnosis of NSTEMI. The document then outlines her pharmacological management including antiplatelet therapy, anticoagulation, beta-blockers, ACE inhibitors and statins as well as her appropriate treatment options going forward.
This case discusses an 18-year-old female patient presenting with easy fatigability and other symptoms over several months. After examination and investigations, she was diagnosed with systemic lupus erythematosus affecting multiple organs including the lungs, skin, kidneys, and central nervous system. She was started on treatment including steroids, antibiotics, and other medications. The case highlights the approach to diagnosing and managing SLE, a chronic autoimmune disease with diverse clinical manifestations and organ involvement.
The document discusses lupus, an autoimmune disease that commonly affects the kidneys and can lead to end-stage renal disease requiring dialysis or transplantation. Kidney involvement from lupus nephritis is a major cause of illness and death, and the document outlines risk factors for progression to end-stage renal disease as well as treatment options and outcomes for lupus patients with kidney failure.
Robin Lachmann, MD, PhD, and Melissa Wasserstein, MD, prepared useful Practice Aids pertaining to acid sphingomyelinase deficiency for this CME activity titled “Assessing the Potential Role of Emerging Therapies in the Early Diagnosis and Optimal Management of Chronic Visceral Acid Sphingomyelinase Deficiency.” For the full presentation, complete CME information, and to apply for credit, please visit us at https://bit.ly/35KVwoE. CME credit will be available until June 3, 2021.
1) Heart failure is a major and growing public health problem, affecting over 15 million people in Europe with a prevalence of over 2-3% overall and 10-20% in those over 70 years old.
2) It is a primary cause of hospital admissions and readmissions, accounting for 5% of admissions and 40% of patients being readmitted or dying within a year. It represents a significant cost burden on healthcare systems.
3) Diagnosis involves clinical examination, ECG, chest x-ray, echocardiography and natriuretic peptide levels of BNP or NT-proBNP which can help differentiate between possible and likely heart failure.
4) Heart failure is now recognized as a
This document discusses diabetes as a risk factor for atherosclerotic vascular disease. It covers the classification of diabetes, how diabetes affects micro and macrovascular systems, and the pathophysiology involved in increased vascular risk. Evaluation and treatment approaches for diabetes patients with vascular complications are also reviewed, including the importance of glycemic control, risk factor modification, and exercise therapy.
This document describes a case of a 70-year-old male farmer who presented with decreased urine output, leg swelling, and facial puffiness for one week. Laboratory tests revealed severe iron deficiency anemia, proteinuria, and impaired kidney function. A renal biopsy showed necrotizing and crescentic glomerulonephritis. P-ANCA was positive. The patient was diagnosed with ANCA-associated necrotizing crescentic glomerulonephritis and treated with steroids, cyclophosphamide, and plasma exchange. His kidney function improved but he later died at home for unclear reasons.
This randomized controlled trial evaluated the effect of dapagliflozin versus placebo on worsening heart failure or cardiovascular death in patients with heart failure and an ejection fraction above 40%. It found that dapagliflozin reduced the risk of the primary composite outcome compared to placebo, both in the overall population and in those with an ejection fraction under 60%. Dapagliflozin also reduced the risk of worsening heart failure alone. There was no significant difference in cardiovascular death or adverse events between the groups. The authors concluded that dapagliflozin lowered the risk of worsening heart failure or cardiovascular death regardless of ejection fraction.
This document discusses Mixed Connective Tissue Disease (MCTD), which has features of systemic lupus erythematosus, systemic sclerosis, and polymyositis. It was identified in 1972 and is characterized by high levels of anti-U1 snRNP antibodies. Common symptoms include Raynaud's phenomenon, swollen fingers, and mixed features of the three diseases. Prognosis is generally good, though some patients develop severe and life-threatening complications such as pulmonary hypertension. Treatment focuses on controlling symptoms and complications.
Membranous nephropathy is a common cause of nephrotic syndrome in adults. It has variable natural history, with about 1/3 of patients achieving spontaneous remission, 1/3 having persistent proteinuria but stable renal function, and 1/3 progressing to end-stage renal disease over 5-10 years. Several factors predict poorer prognosis, including older age, nephrotic syndrome, lower serum albumin and higher proteinuria levels. Studies show immunosuppressive therapy may alter the natural history for patients at high risk of progression, but risks of treatment must be weighed against the likelihood of spontaneous remission.
This document discusses the management of diabetic nephropathy. It begins with defining diabetic nephropathy as a clinical syndrome characterized by persistent albuminuria, progressive decline in glomerular filtration rate, elevated blood pressure, worse glycemic control, hypertension, and genetic predisposition. It then outlines the typical progression of diabetic kidney disease and reviews risk factors. Current treatment strategies are aimed at strict glycemic control, blood pressure control, reducing proteinuria, and preserving renal function through ACE inhibitors, ARBs, and lifestyle modifications like weight loss and smoking cessation. Newer treatments continue to be explored, but therapeutic intervention works best when begun early and glycemia, blood pressure, and proteinuria are well controlled.
A proper description about Rheumatic arthritis. It containts DEFINITION, EPIDEMIOLOGY, ETIOLOGY, RISK FACTORS, PATHOPHYSILOGY, SIGN & SYMPTOMS, DIAGNOSIS, TREATMENT & DIFFERENCES BETWEEN RA & OA
This document discusses the clinical features and treatment of ANCA-associated vasculitis. It begins by defining vasculitis and describing the different types. It then focuses on ANCA-associated vasculitis, describing the characteristics of Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA). For treatment, it recommends cyclophosphamide or rituximab combined with steroids for inducing remission of GPA and MPA. Azathioprine or methotrexate are used to maintain remission. EGPA is primarily treated with steroids, with cyclophosphamide added for more
This summary outlines the key findings of the EMPA-KIDNEY trial which evaluated the effect of empagliflozin treatment on kidney disease progression and cardiovascular outcomes in patients with chronic kidney disease (CKD). The randomized, double-blind trial involved over 6,600 patients with CKD across 8 countries. Patients received either empagliflozin 10mg or placebo daily. The primary outcome of kidney disease progression or cardiovascular death occurred in 13.1% of the empagliflozin group versus 16.9% of the placebo group, representing a 28% lower risk with empagliflozin. Secondary outcomes also favored empagliflozin treatment, including lower rates of hospitalization. The benefits were
Evolocumab is a PCSK9 inhibitor monoclonal antibody that significantly lowers LDL-C levels and cardiovascular risk. The FOURIER trial evaluated evolocumab in 27,564 high-risk patients on statin therapy and found it reduced LDL-C by 59% and the relative risk of the primary composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% compared to placebo. Evolocumab provides an important additional treatment option for lowering LDL-C and cardiovascular risk beyond statin therapy alone.
Similar to Scleroderma: State of the Art Management (20)
This talk was presented by Michael Macklin, MD from the University of Chicago at the Scleroderma Patient Education Conference on May 4, 2024, hosted by the Scleroderma Foundation of Greater Chicago. This talk includes:
Overview of scleroderma manifestations, organ involvement, brief classifications (limited, diffuse, sine scleroderma)
Overview of current treatment options, need for additional therapies
Overview of plan for multi-disciplinary scleroderma center at the University of Chicago
Potential future therapies in the literature at large
Planned trials/future treatment options at the University of Chicago
For more info about scleroderma and the foundation, head to www.stopscleroderma.org
Interstitial lung disease (ILD) is a common complication of scleroderma that leads to inflammation and scarring of the lungs. In this session, we will review the prevalence of scleroderma-associated ILD (SSc-ILD), classic symptoms, and the approach to evaluating patients with suspected disease. In addition, we will cover various treatments available for patients with SSc-ILD.
This talk was presented at the Scleroderma Patient Education Conference on May 4, 2024, hosted by the Scleroderma Foundation of Greater Chicago.
For more info about scleroderma and the foundation, head to www.stopscleroderma.org
Overview of scleroderma manifestations, organ involvement, brief classifications (limited, diffuse, sine scleroderma). Overview of current treatment options, need for additional therapies. Overview of plan for multi-disciplinary scleroderma center at the University of Chicago. Potential future therapies in the literature at large. Planned trials/future treatment options at the University of Chicago.
For more info about scleroderma and the foundation, head to www.stopscleroderma.org
This talk was presented at the Scleroderma Patient Education Conference on May 4, 2024, hosted by the Scleroderma Foundation of Greater Chicago.
This session will discuss modalities and demonstrate exercises to improve movement and function in the hands, face and mouth. Suggestions will be also be provided on the use of assistive devices and alternate techniques to accomplish tasks of daily living to increase independence and protect the hands.
This presentation was held on May 4, 2024 by the Scleroderma Foundation of Greater Chicago.
For more information on the foundation and scleroderma, head to our website at www.stopscleroderma.org
Chronic pain is common. If we don’t suffer from it ourselves, chances are we know someone who does. Changes in the structure and function of the brain are thought to underlie chronic pain. The good news is that these changes are not hardwired. Many things can be done to influence how the brain processes pain signals including exercise, healthy eating, and better sleep, as well as thinking more adaptive thoughts, positive emotions, and feeling love and connected. This session will highlight the neuroscience related to chronic pain and how engaging in simple self-management strategies can result in less pain and a more rewarding life.
This presentation comes from the Spring Patient Education conference presented by the Scleroderma Patient Education Conference presented by the Scleroderma Foundation of Greater Chicago.
See the slides from the Scleroderma Foundation of Greater Chicago's Workshop: Improving Mental Health with Chronic Illness. This presentation was held by the mental health professionals at Ellie Mental Health.
Learn from Bethany Doerfler, MS, RD, LDN, a registered dietitian whose clinical practice and research focuses on providing wellness-based medical nutrition therapy for digestive disorders and allergic bowel diseases. She currently practices in the Division of Gastroenterology and Hepatology at Northwestern Medicine in Chicago, IL. She is the first dietitian to be fully integrated into a gastroenterology division for both research and patient care. This presentation is optimized for Scleroderma patients to learn about their diet options to improve scleroderma symptoms and their gut health.
This presentation covers gastrointestinal issues, which are commonly experienced by those living with scleroderma. This session is set to be an invaluable resource for patients and caregivers, as it will provide crucial insights and approaches to managing GI issues effectively. Dr. Khanna's vast knowledge and experience make this talk a must-attend event for anyone seeking to enhance their understanding and management of GI symptoms in scleroderma.
This document discusses calcinosis, a complication of scleroderma where calcium deposits form in the soft tissues. It outlines that calcinosis most commonly affects the hands, joints, knees and muscles. While the calcium levels in the blood are normal, inflammation and low blood flow in tissues are thought to contribute to calcinosis formation. The deposits contain bone-like proteins and crystals. 18F-NaF PET imaging may help detect early or active calcinosis. Treatments discussed include protecting joints, surgical removal of deposits, topical or injected sodium thiosulfate, medications like tofacitinib, NSAIDs, colchicine and minimizing scleroderma complications to reduce calcinosis risk over
This talk will center around the crucial topic of interstitial lung disease (ILD). Gain invaluable insights into the latest advancements in ILD management, potential treatment options, and the importance of clinical trials in advancing care for scleroderma patients.
Dr. Cuttica and Dr. Mylvaganam will co-lead an insightful talk on pulmonary hypertension (PH). Attendees will have the opportunity to learn about pulmonary hypertension, one of the most serious conditions that impact individuals with scleroderma. The talk will give an overview of pulmonary hypertension and potential treatment options.
In this talk we will discuss the most common findings associated with scleroderma. We will discuss some of the methods your dental team can utilize to help manage your condition, and also some ways that you can help yourself and your dental team manage your condition. We will discuss some unique methods for maintaining your oral health care and will conclude with an open Q&A session.
Virtually every aspect of systemic sclerosis can be beneficially impacted by exercise: inflammation, circulation, body warmth, GI, skin, musculoskeletal and lung health.
The therapeutic underpinnings of exercise target the specific mechanisms behind the pervasive SSc-disease biological, physical and psychological manifestations.
This session is intended to empower people living with scleroderma with knowledge of systemic sclerosis and the anticipated impact exercise and physical activity can have on the many manifestations of systemic sclerosis.
At the end of this session, attendees should have a better understanding of the extent of SSc and feel confident in constructing an exercise regimen generally and for their particular needs related to scleroderma.
In this talk, Dr. Brown will expand your knowledge of how scleroderma impacts the GI tract. This presentation is crucial as an estimated 90% of scleroderma patients suffer from gastrointestinal complications.
Dr. Brown is well-known for his exceptional ability to make complex medical information easy to understand.
Presented by Murray Baron, MD at the Scleroderma Patient Education Conference, hosted by the Scleroderma Foundation Greater Chicago Chapter on Saturday, October 12, 2019 in Chicago, IL. For more about the foundation visit scleroderma.org/chicago.
Presented by Jennifer Mundt, PhD at the Scleroderma Patient Education Conference, hosted by the Scleroderma Foundation Greater Chicago Chapter on Saturday, October 12, 2019 in Chicago, IL.
This document summarizes a presentation on recent developments in treating scleroderma interstitial lung disease. It discusses that ILD affects the lung interstitium and causes decreased oxygen transfer and stiff lungs. ILD risk is higher in patients with autoantibodies like anti-Scl-70. New data shows that long-term lung function loss predicts benefit from anti-fibrotic drugs. The Senscis trial found that nintedanib slowed lung function decline in SSc-ILD patients. Hematopoietic stem cell transplant trials like ASTIS and SCOT showed reduced mortality compared to controls, but transplant-related mortality remains a concern. A new Scleroderma Lung Study trial will test pirfen
This document provides an overview of gastrointestinal manifestations and treatment in scleroderma. It discusses how 60-90% of scleroderma patients experience GI involvement, most commonly affecting the esophagus, stomach, small intestine, and colon. For the esophagus, it covers GERD, dysphagia, and their diagnostic tests and treatments like PPIs. For the stomach, it discusses gastroparesis, GAVE, and treatments like prokinetic agents and APC. It reviews SIBO, CIPO, and treatments for the small intestine. For the colon and anus, it covers constipation, fecal incontinence, diagnostic tests, and treatments including laxatives, bio
Presented by Dr. JoAnna Harper, PharmD at the Scleroderma Patient Education Conference hosted by the Scleroderma Foundation Greater Chicago Chapter on April 27, 2019 in Oakbrook, IL.
More from Scleroderma Foundation of Greater Chicago (20)
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
1. Mary E. Strek, MD
Professor of Medicine
University of Chicago Medicine
Scleroderma:
State of the Art Management
April 16, 2016
2. Pulmonary Complications of Scleroderma
Common and under recognized
May not track with other manifestations
Impair quality of life
May masquerade as “idiopathic” disease
- Forme fruste (incomplete or atypical form)
- Presenting manifestation
- Lung dominant or limited
MAY BE TREATABLE!
3. Pulmonary Complications in CTD
Disease Antibody Airway ILD Vascular Pleural
RA RF, aCCP Bronchiolitis,
Bronchiectasis
UIP Secondary Effusions
SLE ANA, dsDNA, Smith Bronchiolitis Not
common
Primary
Alveolar
Hemorrhage
Effusions
Scleroderma ANA, Scl-70
Anticentromere (PAH)
Rare fNSIP
UIP
Secondary
Primary
Rare
MCTD ANA, RNP Not
common
fNSIP Primary
Secondary
Not
common
DM/PM ANA, SS-A, Jo-1
Myositis panel
Rare OP
NSIP
UIP
DAD
Secondary Rare
Sjogren’s ANA, SS-A, SS-B Bronchiectasis NSIP
LIP
UIP
Secondary Not
common
4. Systemic Sclerosis (SS): Classification Criteria
- Definite SS 9≥
Van den Hoogen, Ann Rheum Dis 2013;72:1747
5. Systemic Sclerosis Sine Scleroderma
Originally described 40 years ago
Uncommon variant of limited scleroderma
- No sclerodactyly but skin thickening/digital edema
- Interstitial lung disease in > 80%
Positive ANA > 93%
Non-specific interstitial pneumonia (NSIP)
9. Scleroderma: Pulmonary Manifestations
Interstitial lung disease (ILD) is very common
Esophageal dysfunction and aspiration
Pulmonary HTN alone and with ILD
Airway disease
- Obstructive lung disease (follicular bronchiolitis)
Pleuritis
Pulmonary “scar” carcinoma
Restriction of chest wall or respiratory muscle weakness
10. Scleroderma: Phenotypes
Solomon Eur Resp Rev 2013;22:6-19
Wigley, Mayo Clin Proc 2013; 88:377-393
Interstitial Lung Disease Pulmonary Hypertension
Pathogenesis Activation of lung fibroblasts
pulmonary fibrosis
Injury to vascular endothelium
arterial fibrosis
Prevalence 40-75% PFTs
90% CT
13-35% ECHO
7-13% RHC
Associated with Antitopoisomerase I (SCL-70) Anticentromere
Cause of death in SSc 35% 30%
Compared to idiopathic ILD SSc-ILD improved survival SSc-PH worse survival
11. Scleroderma Associated ILD
Physical exam/labs
- Clubbing uncommon/Raynaud’s phenomenon frequent
- anti-Scl-70 antibody correlates with ILD (seen 1/3rd
)
Pulmonary function abnormalities
- Decreased TLC in 32 – 67% patients
- Decreased FVC in up to 77% patients
- Decreased DLCO in 90%
Major histopathologic patterns
- NSIP most common (56% vs 72% vs 76%)
- Most cases fibrotic (vs cellular) NSIP
- UIP pattern (honeycombing on HRCT)
17. Scleroderma ILD: Prognosis
Progresses to severe ILD in 15%
May be rapidly progressive in 1st
2 years
- HRCT with ground-glass opacities
- PFT’s show decline in FVC or diffusing capacity
Gradual decline in lung function or stable disease in others
ILD may affect survival
- PFT’s predictive
- Prognosis may be better if NSIP noted on biopsy
23. Cyclophosphamide (Cytoxan)
Potent but toxicity limits long-term use
Nitrogen mustard like alkylating agent
Progressive reduction in B and T lymphocytes
500 to 750 mg/m2
BSA IV then monthly bolus
May increase dose up to 1 g/m2
BSA
Decrease dose renal insufficiency
Marder, Semin Respir Crit Care Med 2007; 28:398-417
24. Cyclophosphamide
MAJOR TOXICITY: Bone marrow, hemorrhagic cystitis
(can be fatal)
Hydration! Urine output > 100 mL/h
In ICU may need catheter drainage and bladder irrigation
OTHER TOXICITIES: Infection, infertility, pulmonary,
Cancers (bladder, cervix, skin, leukemia)
MONITOR: CBC, renal function and UA weekly then every
2 weeks, periodic LFT’s
Urine cytology and PAP smears annually
25. Scleroderma Lung Study
Double-blind, randomized placebo controlled trial
Effect of oral cyclophosphamide (CYC) vs placebo
Study design:
- Scleroderma and dyspnea
- Restriction on PFT’s (FVC 45-85%/DLCO >30% predicted)
- Inflammatory ILD on BAL or ground-glass on HRCT
- CYC 2mg/kg/day (average dose 100mg) or placebo for 1 year
- 2nd
year follow-up OFF therapy
- Primary end-point FVC at 12 months
Conducted by NIH at 13 centers
Tashkin, NEJM 2006; 354:2655
26. Scleroderma Lung Study
Results:
- Screened 267 pts, 158 randomized
- Baseline characteristics matched; disability score lower placebo
- 54 pts in CYC and 55 in placebo completed study
Mean adjusted absolute difference in FVC at 12 months
2.53% (95% CI, 0.28 to 4.79%) favoring CYC (P<0.03)
Adverse events greater in CYC group (hematuria,
leukopenia, anemia, pneumonia) and 3 malignancies
(bladder, vulvar, angiosarcoma scalp)
28. Mycophenolate Mofetil (CellCept)
Potent and well tolerated
Inhibits critical enzyme in purine synthesis in activated lymphocytes
Starting dose 500 mg BID, target dose 1000 mg BID
Great variability serum levels in patients on same dose
TOXICITIES: GI, Infections, Leukopenia less common
Lower rate side effects: hospitalizations, GI, infections, amenorrhea
If GI toxicity: decrease dose, more freq intervals (TID)
MONITOR: CBC after dose change then monthly
EXPENSIVE so insurance may not cover
TERATOGENIC/PREGNANCY CATEGORY X
Marder, Semin Respir Crit Care Med 2007; 28:398-417
31. Azathioprine (Imuran)
Less potent and slower onset of action cyclophosphamide
Metabolized to purine antagonist 6-mercatopurine
Inhibits both cellular and humoral immunity
Starting dose 50 mg daily,1.5-2 mg/kg (maximum 200 mg)
daily
Low thiopurine methotransferase level increase risk BM
toxicity
TOXICITIES: Bone marrow, liver, infection, cancer?
MONITOR: CBC, LFTs after dose change then monthly
Marder, Semin Respir Crit Care Med 2007; 28:398-417
32. • Nintedanib
– Tyrosine kinase inhibitor
– DOSE 150 mg BID, can reduce to 100 mg BID
– MONITOR Liver function monthly x 3 mos then Q 3 mos
• Pirfenidone
– Antifibrotic effects
– DOSE 267 mg TID x 2 weeks, then 534 mg TID x 2 weeks,
then 801 mg TID
– MONITOR Liver function monthly x 6 mos then Q 3 mos
Overview FDA approved IPF Meds
34. Adverse
EffectsDRUG ADVERSE
EFFECT
DOSE
MODIFICATION
ADDITIONAL
MEASURES
NINTEDANIB Diarrhea Reduce dose Imodium
N/abdominal pain Reduce dose/food PPI, H2 blocker
Arterial thrombosis Caution in high risk
cardiovascular disease
Monitor for cardiac
events
Elevated LFTs Reduce or interrupt dose Monitor LFTs
DRUG
INTERACTIONS
Ketoconazole, Emycin,
carbamazepine,
phenytoin, rifampin
Avoid with
anticoagulants?
PIRFENIDONE N/V/anorexia Reduce dose/food PPI, H2 blocker
Rash HOLD drug Avoid sunlight
Elevated LFTs Reduce or interrupt dose Monitor LFTs
Agranulocytosis STOP DRUG Monitor CBC?
DRUG
INTERACTIONS
Fluvoxamine Avoid Ciprofloxacin
35. Scleroderma Associated Pulm HTN
Often unrelated to ILD
Risk factors- Raynaud’s, limited scleroderma,
anticentromere Ab
PFT’s
- FVC 80% predicted
- DLCO 40%predicted
Often severe
- HFpEF common
- High frequency pericardial disease
- Echo may not correlate
- Treatment responsive
37. GERD: Management
Weight loss if obese
Elevate head of bed
Avoid eating 2-3 hrs before lying down
Eliminate foods (caffeine, ETOH etc) that trigger reflux
Proton pump inhibitor 30-60 min before first meal day
Prokinetic agent
Nissan fundoplication often not an option due to
dysmotility
Katz, Am J Gastroenterol 2013; 108:308-328
Acid reflux is common in IPF
May be clinically silent
Evidence of increased acid exposure in IPF vs ILD
Hiatal hernia more common (39%) in IPF vs COPD 13.3% or asthma (16.67%)
Microaspiration may play a role in pathogenesis
Could this contribute to acute exacerbations?